261 related articles for article (PubMed ID: 7912568)
1. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma--results of a multiparametric study.
Bevilacqua P; Barbareschi M; Verderio P; Boracchi P; Caffo O; Dalla Palma P; Meli S; Weidner N; Gasparini G
Breast Cancer Res Treat; 1995; 36(2):205-17. PubMed ID: 8534868
[TBL] [Abstract][Full Text] [Related]
3. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
[TBL] [Abstract][Full Text] [Related]
4. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.
Levesque MA; Clark GM; Yu H; Diamandis EP
Br J Cancer; 1995 Sep; 72(3):720-7. PubMed ID: 7545416
[TBL] [Abstract][Full Text] [Related]
5. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of p53 expression in early-stage breast-carcinoma compared with tumor angiogenesis, epidermal growth-factor receptor, C-erbb-2, cathepsin-d, DNA-ploidy, parameters of cell-kinetics and conventional features.
Gasparini G; Bevilacqua P; Boracchi P; Maluta S; Pozza F; Barbareschi M; Dallapalma P; Mezzetti M; Harris A
Int J Oncol; 1994 Jan; 4(1):155-62. PubMed ID: 21566906
[TBL] [Abstract][Full Text] [Related]
7. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
Lipponen P; Eskelinen M
Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031
[TBL] [Abstract][Full Text] [Related]
8. Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study.
Toi M; Tominaga T; Osaki A; Toge T
Breast Cancer Res Treat; 1994 Jan; 29(1):51-8. PubMed ID: 7912567
[TBL] [Abstract][Full Text] [Related]
9. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
10. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
11. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer.
Yu H; Levesque MA; Khosravi MJ; Papanastasiou-Diamandi A; Clark GM; Diamandis EP
Br J Cancer; 1996 Oct; 74(8):1242-7. PubMed ID: 8883411
[TBL] [Abstract][Full Text] [Related]
12. Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer.
Railo M; Lundin J; Haglund C; von Smitten K; von Boguslawsky K; Nordling S
Acta Oncol; 1997; 36(4):369-74. PubMed ID: 9247096
[TBL] [Abstract][Full Text] [Related]
13. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of prognostic factors in operable breast cancer.
Hawkins RA; Tesdale AL; Killen ME; Jack WJ; Chetty U; Dixon JM; Hulme MJ; Prescott RJ; McIntyre MA; Miller WR
Br J Cancer; 1996 Nov; 74(9):1469-78. PubMed ID: 8912547
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
16. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
Gasparini G; Weidner N; Bevilacqua P; Maluta S; Dalla Palma P; Caffo O; Barbareschi M; Boracchi P; Marubini E; Pozza F
J Clin Oncol; 1994 Mar; 12(3):454-66. PubMed ID: 7509851
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status.
Sacks NP; Smith K; Norman AP; Greenall M; LeJeune S; Harris AL
Eur J Cancer; 1993; 29A(3):426-8. PubMed ID: 8398346
[TBL] [Abstract][Full Text] [Related]
18. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
19. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
[TBL] [Abstract][Full Text] [Related]
20. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
Archer SG; Eliopoulos A; Spandidos D; Barnes D; Ellis IO; Blamey RW; Nicholson RI; Robertson JF
Br J Cancer; 1995 Nov; 72(5):1259-66. PubMed ID: 7577479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]